Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 19/20 | 0.70 |
| ▸ | PTPN1 | P18031 | 19/20 | 0.70 |
| ▸ | PTPN2 | P17706 | 18/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | HSPD1 | P10809 | 10/20 | 0.67 |
| ▸ | HSPE1 | P61604 | 10/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111491 | 0.84 | PTPN5 (0.71) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL24295077 | 0.79 | PTPN1 (0.63) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL24155564 | 0.79 | NPC1 (0.67) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL31170 | 0.78 | NPC1 (0.81) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL30684942 | 0.78 | PTPN1 (0.80) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL8120431 | 0.78 | PTPN1 (0.64) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL31476 | 0.77 | NPC1 (0.79) | PTPN5PTPN1PTPN2MEN1MAPT | |
| Methane SCHEMBL29265168 | 0.77 | NPC1 (0.79) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL20656686 | 0.76 | BCHE (0.66) | PTPN5PTPN1PTPN2MEN1MAPT | |
| SCHEMBL1660542 | 0.76 | NPC1 (0.67) | PTPN5PTPN1PTPN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812319-B9 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2003-10-08 | — | — | EP | claimed |
| EP-0812319-B1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2002-07-10 | — | — | EP | claimed |
| US-6034246-A | ANTICANCER AGENT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-03-07 | — | — | US | claimed |
| EP-0812319-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-12-17 | — | — | EP | claimed |
| WO-1996026932-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | claimed |
| EP-0812319-B9 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2003-10-08 | — | — | EP | disclosed |
| EP-0812319-B1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RES VENTURES LTD (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-6034246-A | ANTICANCER AGENT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-03-07 | — | — | US | disclosed |
| EP-0812319-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996026932-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | disclosed |